Eupraxia Pharmaceuticals Advances Trial in Eosinophilic Esophagitis

Eupraxia Pharmaceuticals is making significant progress with its EP-104GI treatment and has now commenced the second cohort of its early-stage trial in eosinophilic esophagitis.

Dose Escalation Approved by Safety Review Committee

Following the favorable outcomes observed in the trial's first cohort, Eupraxia's safety review committee has granted approval for a dose escalation in the second cohort. Notably, EP-104GI has been proven to be well tolerated, with no drug-related adverse events reported.

Protocol Amendment Submitted for Enhanced Assessments

To further enhance the trial's efficacy assessment and better understand its pharmacokinetics, Eupraxia has submitted an amendment to the protocol. This amendment includes additional assessments to be conducted at the six-month mark across all cohorts.

Trial Details and Enrollment

The Phase 1b/2a trial adopts a dose-ascending approach and consists of three patients per cohort. With a maximum of five cohorts, Eupraxia aims to have a total enrollment of up to 15 patients from esteemed medical centers in Canada, the Netherlands, and Australia.

Building on Success in Osteoarthritis Treatment

The initiation of the second cohort follows the recent completion of a Phase 2b clinical trial for Eupraxia's lead product candidate, EP-104IAR. This innovative treatment targets pain relief in individuals with osteoarthritis of the knee.